Download PDF
Thromb Haemost 1998; 80(03): 530
DOI: 10.1055/s-0037-1615249
Letters to the Editor
Schattauer GmbH

Fatal Danaparoid-sodium Induced Thrombocytopenia and Arterial Thromboses

Bernard Tardy
1   From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
,
Brigitte Tardy-Poncet
1   From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
,
Alain Viallon
1   From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
,
Michèle Piot
1   From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
,
Eliane Mazet
1   From the Groupe de Recherche sur la Thrombose, Centre Hospitalier et Universitaire de Saint Etienne, France
› Author Affiliations
Further Information

Publication History

Received 19 March 1998

Accepted after revision 07 May 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Magnani HN. Heparin-induced thrombocytopenia: an overview of 230 patients treated with danaparoid-sodium (Org 10172). Thromb Haemost 1993; 70: 554-61.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Tardy-Poncet B. French experience in the use of danaparoid-sodium as an alternative antithrombotic treatment for patients with heparin induced thrombocytopenia. Thromb Haemost 1998 (Suppl) 1825a.
    PubMedGoogle Scholar
  • 3 Warkentin TE. Danaparoid (Danaparoid-sodium) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin significance of in vitro cross-reactivity of danaparoid for HIT-IgG. Blood 1996; 88 (Suppl. 01) 626a.
    PubMedGoogle Scholar